Medicinal Chemistry
Scope & Guideline
Catalyzing breakthroughs in drug formulation and discovery.
Introduction
Aims and Scopes
- Drug Design and Synthesis:
The journal emphasizes the design and synthesis of new chemical entities with potential therapeutic applications, employing advanced synthetic methodologies and innovative chemical strategies. - Structure-Activity Relationships (SAR):
Research often includes detailed studies on the structure-activity relationships of compounds, aiming to optimize their pharmacological properties and efficacy. - Biological Evaluation:
Papers frequently report on the biological evaluation of newly synthesized compounds, including in vitro and in vivo studies, to assess their therapeutic potential against various diseases. - Target Identification and Mechanism of Action:
The journal covers studies that identify biological targets for new drugs and elucidate their mechanisms of action, contributing to a deeper understanding of drug efficacy. - Natural Products and Derivatives:
There is a notable interest in the modification and evaluation of natural products, exploring their potential as leads for new drug development. - Interdisciplinary Approaches:
The journal promotes interdisciplinary research that combines medicinal chemistry with molecular biology, pharmacology, and computational modeling to enhance drug discovery efforts.
Trending and Emerging
- PROTACs and Targeted Protein Degradation:
There is a growing interest in the development of PROTACs (proteolysis-targeting chimeras) as a novel strategy for targeted protein degradation, which has become a significant focus in cancer therapeutics. - Nanotechnology in Drug Delivery:
Emerging research highlights the application of nanotechnology for targeted drug delivery systems, enhancing the efficacy and reducing the side effects of therapeutic agents. - Biologics and Bioconjugates:
The rise of biologics, including monoclonal antibodies and their conjugates, is evident, with research increasingly focusing on their design, synthesis, and therapeutic applications. - Antiviral Drug Development:
In light of recent global health challenges, there has been a marked increase in research aimed at developing antiviral agents, particularly against emerging viruses like SARS-CoV-2. - Artificial Intelligence in Drug Discovery:
The integration of artificial intelligence and machine learning in drug design and discovery processes is becoming a prominent theme, facilitating faster and more efficient identification of potential drug candidates. - Focus on Multi-Target Agents:
There is an emerging trend towards the design of multi-target agents that can simultaneously address multiple pathways or mechanisms, reflecting a shift in the approach to complex diseases.
Declining or Waning
- Traditional Small Molecule Inhibitors:
Research focusing solely on traditional small molecule inhibitors without novel modifications or innovative delivery systems seems to be less common, as the field shifts towards more complex and multifunctional agents. - Single Target Drug Development:
There is a noticeable decrease in studies centered around single-target drug development, as the trend moves towards multitargeted approaches and polypharmacology to address complex diseases. - Basic Pharmacokinetic Studies:
Papers that solely focus on basic pharmacokinetic studies without integrating them into broader drug design or therapeutic efficacy are becoming less common, signaling a shift towards more comprehensive evaluations. - Conventional Synthetic Methodologies:
The reliance on conventional synthetic methods without exploration of green chemistry or novel synthetic strategies appears to be waning, as there is increasing emphasis on sustainability and efficiency in drug synthesis.
Similar Journals
BIOORGANIC & MEDICINAL CHEMISTRY
Innovating Drug Discovery Through ChemistryBIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.
RSC Medicinal Chemistry
Connecting Disciplines for Breakthrough MedicinesRSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.
Pakistan Journal of Pharmaceutical Sciences
Innovating the future of drug development and science.Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
Exploring the Essence of Asian Natural InnovationsJOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH is a prestigious publication in the field of natural products, focusing on valuable research spanning analytical chemistry, pharmacology, and complementary medicine. Published by Taylor & Francis Ltd in the United Kingdom, this journal has established itself as a key resource for academics and professionals seeking to explore advancements in drug discovery and organic chemistry. With a converged publication timeline from 1998 to 2024, the journal boasts several commendable category quartiles as of 2023, reflecting its robust standing in the research community: Q2 in Complementary and Alternative Medicine, Q3 in multiple domains including Analytical Chemistry and Organic Chemistry, and Q4 in Molecular Medicine. Although it currently does not offer open access, the journal remains a valuable compendium for empirical research and innovative studies in areas such as pharmacology and medicinal chemistry. Researchers, professionals, and students alike will find the JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH to be an essential platform for sharing groundbreaking findings and fostering collaborations that lead to significant advancements in science and health.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Advancing the frontiers of medicinal chemistry.BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading journal in the fields of biochemistry, drug discovery, and medicinal chemistry, designed to disseminate significant advances in these disciplines. Established in 1991, the journal spans various important categories, including Organic Chemistry and Pharmaceutical Science, with its 2023 Scimago Journal Rank placing it at Q2 in Organic Chemistry and Q3 in several other relevant fields. Though not an open-access publication, it provides invaluable insights into contemporary research and innovative methodologies, appealing to researchers, professionals, and students alike. The journal's commitment to quality and relevance makes it a vital resource for those aiming to stay at the forefront of bioorganic and medicinal chemistry developments. For more information, please visit the journal's website as it remains a critical platform for scholarly exchange, particularly for those engaged in interdisciplinary research.
Anti-Cancer Agents in Medicinal Chemistry
Uncovering the future of anti-cancer strategies.Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.
Acta Pharmaceutica Sinica B
Unlocking New Horizons in Pharmacology and ToxicologyActa Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.
DRUG AND CHEMICAL TOXICOLOGY
Innovating research for a healthier tomorrow.Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.
MEDICINAL RESEARCH REVIEWS
Exploring Breakthroughs in Drug Discovery and PharmacologyMEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.
CURRENT DRUG TARGETS
Pioneering Discoveries in Drug DevelopmentCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.